ValuEngine Lowers Blueprint Medicines (BPMC) to Sell

ValuEngine cut shares of Blueprint Medicines (NASDAQ:BPMC) from a hold rating to a sell rating in a research report sent to investors on Friday morning.

Several other brokerages also recently commented on BPMC. Wedbush reiterated an outperform rating and issued a $82.00 target price (up previously from $70.00) on shares of Blueprint Medicines in a report on Monday, November 6th. Cowen reiterated a buy rating on shares of Blueprint Medicines in a report on Tuesday, October 31st. DA Davidson assumed coverage on shares of Blueprint Medicines in a research report on Friday, September 29th. They issued a buy rating and a $90.00 price target on the stock. BTIG Research assumed coverage on shares of Blueprint Medicines in a research report on Friday, September 29th. They issued a buy rating and a $90.00 price target on the stock. Finally, Canaccord Genuity restated a buy rating and issued a $80.00 price target (up from $66.00) on shares of Blueprint Medicines in a research report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. Blueprint Medicines presently has a consensus rating of Buy and an average price target of $70.47.

Shares of Blueprint Medicines (NASDAQ BPMC) traded down $2.24 on Friday, reaching $72.82. 369,200 shares of the company traded hands, compared to its average volume of 427,069. Blueprint Medicines has a 12-month low of $25.08 and a 12-month high of $77.91. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.06). The firm had revenue of $8.07 million during the quarter, compared to the consensus estimate of $5.35 million. Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The business’s revenue was up 31.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.62) EPS. research analysts expect that Blueprint Medicines will post -3.76 EPS for the current fiscal year.

In other news, insider Kate Haviland sold 6,356 shares of Blueprint Medicines stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $60.03, for a total transaction of $381,550.68. Following the sale, the insider now directly owns 6,356 shares in the company, valued at approximately $381,550.68. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Marion Dorsch sold 18,334 shares of Blueprint Medicines stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $65.45, for a total transaction of $1,199,960.30. Following the sale, the insider now owns 18,334 shares in the company, valued at $1,199,960.30. The disclosure for this sale can be found here. Insiders sold a total of 72,639 shares of company stock worth $4,871,743 over the last 90 days. Company insiders own 3.40% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Rockefeller Financial Services Inc. acquired a new position in Blueprint Medicines in the third quarter valued at about $160,000. Turner Investments LLC acquired a new position in Blueprint Medicines in the third quarter valued at about $209,000. Great West Life Assurance Co. Can boosted its position in Blueprint Medicines by 53.6% in the third quarter. Great West Life Assurance Co. Can now owns 3,332 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 1,163 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in Blueprint Medicines by 68.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 1,391 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in Blueprint Medicines in the third quarter valued at about $244,000. Institutional investors and hedge funds own 91.40% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ValuEngine Lowers Blueprint Medicines (BPMC) to Sell” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/12/04/valuengine-lowers-blueprint-medicines-bpmc-to-sell.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

What are top analysts saying about Blueprint Medicines Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Blueprint Medicines Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit